var data={"title":"Prasugrel: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Prasugrel: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/390850?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=prasugrel-patient-drug-information\" class=\"drug drug_patient\">see &quot;Prasugrel: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11238845\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Bleeding risk:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Prasugrel can cause significant, sometimes fatal, bleeding. Do not use prasugrel in patients with active pathological bleeding or a history of transient ischemic attack (TIA) or stroke.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">In patients &ge;75 years, prasugrel is generally not recommended because of the increased risk of fatal and intracranial bleeding and uncertain benefit, except in high-risk situations (patients with diabetes or a history of myocardial infarction [MI]) in which its effect appears to be greater and its use may be considered.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Do not start prasugrel in patients likely to undergo urgent coronary artery bypass graft (CABG) surgery. When possible, discontinue prasugrel at least 7 days prior to any surgery.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Additional risk factors for bleeding include body weight &lt;60 kg, propensity to bleed, and concomitant use of medications that increase the risk of bleeding (eg, warfarin, heparin, fibrinolytic therapy, long-term use of nonsteroidal anti-inflammatory drugs [NSAIDs]).</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Suspect bleeding in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), CABG, or other surgical procedures in the setting of prasugrel.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">If possible, manage bleeding without discontinuing prasugrel. Discontinuing prasugrel, particularly in the first few weeks after acute coronary syndrome (ACS), increases the risk of subsequent cardiovascular events.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7901908\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Effient</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14464693\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Effient</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7910294\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antiplatelet Agent;</li>\n      <li>\n        Antiplatelet Agent, Thienopyridine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7912224\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Acute coronary syndrome (ACS): </b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Percutaneous coronary intervention (PCI) for ACS:</i> Loading dose: 60 mg administered promptly (as soon as coronary anatomy is known) and no later than 1 hour after PCI; Maintenance dose: 10 mg once daily (in combination with aspirin) (ACCF/AHA [O&rsquo;Gara, 2013]; AHA/ACC [Amsterdam 2014]; Levine 2011). For patients with STEMI, a loading dose may also be administered if PCI is performed &gt;24 hours after treatment with a fibrin-specific thrombolytic (ie, alteplase, reteplase, tenecteplase) (ACCF/AHA [O&rsquo;Gara, 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Maintenance dosing in low body weight (ie, &lt;60 kg) individuals:</i> Due to a higher incidence of bleeding in patients weighing &lt;60 kg, a maintenance dose of 5 mg once daily may be considered. In aspirin-treated patients weighing &lt;60 kg (mean: 56.4 &plusmn; 3.7 kg) with stable coronary artery disease, the use of prasugrel 5 mg once daily was shown to reduce platelet reactivity to a similar extent as prasugrel 10 mg administered once daily to patients &gt;60 kg (mean: 84.7 &plusmn; 14.9 kg); clinical events were not evaluated (Erlinge 2012). In patients with ACS (medically managed) treated with aspirin, a 5 mg daily maintenance dose (after a 30 mg loading dose) in patients &lt;60 kg did not demonstrate a significant difference in the composite primary end point of death from cardiovascular causes, MI, or stroke compared to patients &gt;60 kg treated with a 10 mg maintenance dose; bleeding risk was not increased (Roe 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      Duration of prasugrel (in combination with aspirin) after stent placement: Premature interruption of therapy may result in stent thrombosis, MI, and death. According to the ACC/AHA Duration of Dual Antiplatelet Therapy (DAPT) guidelines, at least 12 months of a P2Y12 inhibitor (eg, prasugrel) is recommended for those with ACS receiving either stent type (bare metal [BMS] or drug eluting stent [DES]). The DAPT score may be useful in determining whether to prolong or extend DAPT in patients with stent placement (Yeh 2016). In addition, in patients with DES placement with a high risk of bleeding or significant overt bleeding on DAPT, it may be reasonable to discontinue prasugrel after 6 months of therapy instead (ACC/AHA [Levine 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Conversion from clopidogrel to prasugrel:</i> Beginning 24 hours after the last clopidogrel dose (loading or maintenance), may initiate prasugrel 10 mg once daily or a 60 mg loading dose followed in 24 hours with 10 mg once daily (Angiolillo 2010; Payne 2008; Wiviott 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7910728\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Patients &ge;75 years: Use not recommended; may be considered in high-risk situations (eg, patients with diabetes or history of MI).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7910729\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">No dosage adjustment necessary; use caution in moderate to severe impairment (patients are generally at higher risk of bleeding).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Not dialyzable (NCS/SCCM [Frontera 2016])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7910730\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild to moderate hepatic impairment (Child-Pugh class A and B): No dosage adjustment necessary for mild-to-moderate hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe hepatic impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use caution (patients are generally at higher risk of bleeding).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7910736\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Effient: 5 mg, 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 10 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7910292\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7984963\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM238428.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV68DbkxCmL/yfT5Qc+XtC1KFQ==&amp;TOPIC_ID=9533\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM238428.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7910732\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer without regard to meals. In an emergent primary PCI setting, crushing the tablets (using a commercially available syringe crusher) and mixing with 25 mL of water led to faster absorption and a quicker, more potent antiplatelet effect seen as early as 30 minutes (Rollini 2016). In addition, according to the manufacturer, tablets may be chewed and swallowed (bitter to taste) or crushed and mixed in food or liquid (eg, applesauce, juice, water) and immediately administered by mouth or gastric tube. Administration via an enteral tube that bypasses the acidic environment of the stomach may result in reduced bioavailability of prasugrel (data on file, Daiichi Sankyo-Lilly 2012). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7910296\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Acute coronary syndrome to be managed with percutaneous coronary intervention (PCI):</b> To reduce the rate of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome (ACS) who are to be managed with PCI for unstable angina (UA), non-ST-segment elevation MI (NSTEMI), or ST-elevation MI (STEMI).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10227670\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Prasugrel may be confused with pravastatin, propranolol</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Prasugrel is identified in the Beers Criteria as a potentially inappropriate medication to be used with caution in patients 75 years and older due to increased risk of bleeding in older adults; however, benefit in highest-risk older adults, such as those with prior MI or diabetes, may offset risk.  (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7910605\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (8%), hypotension (4%), atrial fibrillation (3%), bradycardia (3%), peripheral edema (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (6%), dizziness (4%), fatigue (4%), noncardiac chest pain (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypercholesterolemia (&le;7%), hyperlipidemia (&le;7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (5%), diarrhea (2%), gastrointestinal hemorrhage (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Leukopenia (3%), anemia (2%), major hemorrhage (2%), minor hemorrhage (2%), major hemmorhage (life-threatening: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (5%), limb pain (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Epistaxis (6%), dyspnea (5%), cough (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal hepatic function tests, anaphylaxis, angioedema, hematoma, hemoptysis, hemorrhage (requiring inotropes or transfusion), hypersensitivity reaction, intracranial hemorrhage (symptomatic), re-operation due to bleeding, thrombocytopenia, thrombotic thrombocytopenic purpura</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7910301\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity (eg, anaphylaxis) to prasugrel or any component of the formulation; active pathological bleeding (eg, peptic ulcer, intracranial hemorrhage); prior TIA or stroke.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7910302\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding: <b>[US Boxed Warning]: May cause significant, sometimes fatal, bleeding. Do not use prasugrel in patients with active pathological bleeding or a history of TIA or stroke. Additional risk factors for bleeding include body weight &lt;60 kg, propensity to bleed (eg, recent trauma, recent surgery, recent or recurrent GI bleeding, active peptic ulcer disease, severe hepatic impairment, or moderate to severe renal impairment), and concomitant use of medications that increase the risk of bleeding (eg, warfarin, heparin, fibrinolytic therapy, long-term use of NSAIDs). Suspect bleeding in any patient who is hypotensive and has recently undergone coronary angiography, PCI, CABG, or other surgical procedures in the setting of prasugrel. If possible, manage bleeding without discontinuing prasugrel. Discontinuing prasugrel, particularly in the first few weeks after ACS, increases the risk of subsequent cardiovascular events. </b>Management of bleeding episodes includes the use of PRBCs and platelet transfusion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity, including angioedema, has been reported, including in patients with a previous history of thienopyridine hypersensitivity. Because of structural similarities, cross-reactivity is possible among the thienopyridines (clopidogrel, prasugrel, and ticlopidine); use with caution or avoid in patients with previous history of thienopyridine hypersensitivity. Use of prasugrel is contraindicated in patients with hypersensitivity (eg, anaphylaxis) to prasugrel.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombotic thrombocytopenic purpura (TTP): Cases of TTP (usually occurring within the first 2 weeks of therapy), resulting in some fatalities, have been reported with prasugrel; urgent plasmapheresis is required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI disease: Use with caution in patients with recent or recurrent GI bleeding or active peptic ulcer disease (patients are generally at higher risk of bleeding).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment (patients are generally at higher risk of bleeding).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with moderate to severe renal impairment (patients are generally at higher risk of bleeding).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: <b>[US Boxed Warning]: In patients &ge;75 years, use is generally not recommended due to increased risk of fatal and intracranial bleeding and uncertain benefit, except in high-risk situations (patients with diabetes or a history of MI) in which its effect appears to be greater and its use may be considered.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lower GI bleed patients: An individualized and multidisciplinary approach should be utilized to determine therapy discontinuation and management in patients with acute lower GI bleed (LGIB) who are on antiplatelet medications; risk of ongoing bleeding should be weighed with risk of thromboembolic events. In patients receiving dual antiplatelet therapy (aspirin plus P2Y<sub>12</sub> receptor blocker [eg, clopidogrel, prasugrel, ticagrelor, ticlopidine]) or thienopyridine monotherapy, the thienopyridine should generally be resumed as soon as possible and at least within 7 days, taking into account control of bleeding and cardiovascular risk (aspirin should <i>not</i> be discontinued); however, dual antiplatelet therapy should <i>not</i> be discontinued in the 90 days post-acute coronary syndrome or 30 days post-coronary stenting (Strate 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Low-weight patients: In patients weighing &lt;60 kg, risk of bleeding increased; consider lower maintenance dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgical patients: <b>[US Boxed Warning]: Do not initiate therapy in patients likely to undergo urgent CABG surgery; when possible, discontinue &ge;7 days prior to any surgery; increased risk of bleeding.</b> The American College of Chest Physicians (ACCP) recommends discontinuing prasugrel 5 days before surgery (Guyatt 2012). When urgent CABG is necessary, the ACCF/AHA suggests that it may be reasonable to perform surgery within 7 days of discontinuing prasugrel especially if the benefits of prompt revascularization outweigh the risks of bleeding (ACCF/AHA [Hillis 2011]; ACCF/AHA [O&rsquo;Gara 2013]). Elective noncardiac surgery should not be performed in patients in whom dual antiplatelet therapy (DAPT) will need to be discontinued perioperatively within 30 days following bare metal stent (BMS) placement or within 12 months after drug-eluting stent (DES) placement. In patients undergoing urgent noncardiac surgery during the first 4 to 6 weeks after BMS or DES placement, continue DAPT. In patients with stents undergoing surgery that requires discontinuation of the P2Y12 inhibitor (eg, clopidogrel), continue aspirin and re-start the P2Y12 inhibitor as soon as possible after surgery (ACC/AHA [Fleisher 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug discontinuation: Discontinue therapy for active bleeding, elective surgery, stroke, or TIA; reinitiate therapy as soon as possible unless patient suffers stroke or TIA where subsequent use is contraindicated; if possible, manage bleeding without discontinuing therapy since premature discontinuation of treatment may cause increased risk for cardiac adverse events; lapses in treatment should be avoided.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299935\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2B6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2B6 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018470\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9533&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: Antiplatelet Agents (P2Y12 Inhibitors) may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cangrelor: May diminish the antiplatelet effect of Prasugrel. More specifically, while the use of Cangrelor is expected to increase total platelet inhibition in patients who have previously received Prasugrel, Cangrelor is expected to decrease binding of Prasugrel metabolites to P2Y12 receptors and thus reduce the extent of irreversible platelet inhibition. Management: Avoid administration of prasugrel until cangrelor is discontinued.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May decrease serum concentrations of the active metabolite(s) of Prasugrel.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Antiplatelet Agents (P2Y12 Inhibitors) may enhance the adverse/toxic effect of Dabigatran Etexilate. Specifically, the risk of bleeding may be increased. Antiplatelet Agents (P2Y12 Inhibitors) may increase the serum concentration of Dabigatran Etexilate. Specifically, clopidogrel may increase dabigatran serum concentrations.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: Antiplatelet Agents (P2Y12 Inhibitors) may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased.  Management: Carefully consider the anticipated risks and benefits of this combination. If combined, increased monitoring for bleeding is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FentaNYL: May diminish the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors). FentaNYL may decrease the serum concentration of Antiplatelet Agents (P2Y12 Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Morphine (Liposomal): May diminish the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors). Morphine (Liposomal) may decrease the serum concentration of Antiplatelet Agents (P2Y12 Inhibitors). Management: Consider alternative anti-ischemic/analgesic therapies (eg, beta-blockers, nitroglycerin) in patients with acute coronary syndromes treated with a P2Y12 inhibitor when possible. The risks associated with other opioids are unknown.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Morphine (Systemic): May diminish the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors). Morphine (Systemic) may decrease the serum concentration of Antiplatelet Agents (P2Y12 Inhibitors). Management: Consider alternative anti-ischemic/analgesic therapies (eg, beta-blockers, nitroglycerin) in patients with acute coronary syndromes treated with a P2Y12 inhibitor when possible. The risks associated with other opioids are unknown.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RaNITIdine: May decrease serum concentrations of the active metabolite(s) of Prasugrel.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May diminish the antiplatelet effect of Prasugrel.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Antiplatelet Agents (P2Y12 Inhibitors) may enhance the adverse/toxic effect of Rivaroxaban. Specifically, the risk of bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7910298\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Information related to use during pregnancy is limited (Tello-Montoliu, 2012). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20311220\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if prasugrel is excreted in breast milk. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of infant exposure, the benefits of breast-feeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7910734\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Hemoglobin and hematocrit periodically.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7910614\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Prasugrel, an inhibitor of platelet activation and aggregation, is a prodrug that is metabolized to both active (R-138727) and inactive metabolites. The active metabolite irreversibly blocks the P2Y<sub>12</sub> component of ADP receptors on the platelet, which prevents activation of the GPIIb/IIIa receptor complex, thereby reducing platelet activation and aggregation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7910616\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Inhibition of platelet aggregation (IPA): Dose dependent: 60 mg loading dose: &lt;30 minutes; median time to reach &ge;20% IPA: 30 minutes (Brandt, 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak effect: Time to maximal IPA: Dose-dependent: <b>Note:</b> Degree of IPA based on adenosine diphosphate (ADP) concentration used during light aggregometry: 60 mg loading dose: Occurs ~4 hours post administration; Mean IPA (ADP 5 micromole/L): ~84.1%; Mean IPA (ADP 20 micromole/L): ~78.8% (Brandt, 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration of effect: Platelet aggregation gradually returns to baseline values over 5-9 days after discontinuation; reflective of new platelet production </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid; &ge;79%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Active metabolite: V<sub>d</sub>: 44-68 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Active metabolite: ~98%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Rapid intestinal and serum metabolism via esterase-mediated hydrolysis to a thiolactone intermediate (inactive), which is then converted, via CYP450-mediated (primarily CYP3A4 and CYP2B6) oxidation, to an active metabolite (R-138727) (Farid, 2007; Riley, 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Active metabolite: ~7 hours (range 2-15 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Active metabolite: ~30 minutes; With high-fat/high-calorie meal: 1.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~68% inactive metabolites); feces (27% inactive metabolites) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322568\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Effient Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (24): $440.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $550.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Prasugrel HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (30): $495.17</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $495.17</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10962010\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Apagrel (BD, IN, LK);</li>\n      <li>Effient (AR, AU, BB, BR, CN, CO, HK, IL, IN, KR, LB, LK, MY, NZ, PH, SG, TH);</li>\n      <li>Eficlot (LK);</li>\n      <li>Efient (AT, BE, CH, CY, CZ, DE, DK, EE, ES, FR, GB, HR, HU, IE, IS, JP, LT, LU, LV, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR);</li>\n      <li>Hemagrel (BD);</li>\n      <li>Nefagrel (AR);</li>\n      <li>Prasucard (BD);</li>\n      <li>Prasudoc (IN);</li>\n      <li>Prasuva (BD);</li>\n      <li>Reclap (LK);</li>\n      <li>Targol (SY);</li>\n      <li>Trocal (AR);</li>\n      <li>Ugral (LK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>J Am Coll Cardiol</i>. 2014;64(24):2713-2714]. <i>J Am Coll Cardiol</i>. 2014;64(24):e139-e228. doi: 10.1016/j.jacc.2014.09.017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/25260718/pubmed\" target=\"_blank\" id=\"25260718\">25260718</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Angiolillo DJ, Saucedo JF, Deraad R, et al; SWAP Investigators. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (Switching Anti Platelet) study. J Am Coll Cardiol. 2010;56(13):1017-1023. doi: 10.1016/j.jacc.2010.02.072.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/20846599/pubmed\" target=\"_blank\" id=\"20846599\">20846599</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson JL, Adams CD, Antman EM, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2013;127(23):e663-e828. doi: 10.1161/CIR.0b013e31828478ac.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/23630129/pubmed\" target=\"_blank\" id=\"23630129\">23630129</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brandt JT, Payne CD, Wiviott SD, et al, &ldquo;A Comparison of Prasugrel and Clopidogrel Loading Doses on Platelet Function: Magnitude of Platelet Inhibition is Related to Active Metabolite Formation,&rdquo; <i>Am Heart J</i>, 2007, 153(1):66.e9-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/17174640 /pubmed\" target=\"_blank\" id=\"17174640 \">17174640 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Effient (prasugrel) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Erlinge D, Ten Berg J, Foley D, et al. Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial. <i>J Am Coll Cardiol</i>. 2012;60(20):2032-2040. doi: 10.1016/j.jacc.2012.08.964.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/23083774/pubmed\" target=\"_blank\" id=\"23083774\">23083774</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Farid NA, Smith RL, Gillespie TA, et al. The disposition of prasugrel, a novel thienopyridine, in humans. <i>Drug Metab Dispos</i>. 2007; 35(5):1096-1104.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/17403916/pubmed\" target=\"_blank\" id=\"17403916\">17403916</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ferraris VA, Saha SP, Oestreich JH, et al, &ldquo;2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations,&rdquo; <i>Ann Thorac Surg</i>, 2012, 94(5):1761-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/23098967/pubmed\" target=\"_blank\" id=\"23098967\">23098967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo; <i>Circulation</i>, 2012, 126(25):3097-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/23166211/pubmed\" target=\"_blank\" id=\"23166211\">23166211</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;130(24):e278-e333.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/25085961/pubmed\" target=\"_blank\" id=\"25085961\">25085961</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Floyd JS and Serebruany VL, &ldquo;Prasugrel as a Potential Cancer Promoter: Review of the Unpublished Data,&rdquo; <i>Arch Intern Med</i>, 2010, 170(12):1078-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/20585076/pubmed\" target=\"_blank\" id=\"20585076\">20585076</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care.</i> 2016;24(1):6-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/26714677/pubmed\" target=\"_blank\" id=\"26714677\">26714677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grines CL, Bonow RO, Casey DE, et al. AHA/ACC/SCAI/ACS/ADA Science Advisory, Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. A science advisory from the American Heart Association, American College of Cardiology, Society of Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association with representation from The Amercian College Of Physicians. Circulation. 2007;115(6):813-818. Available at http://www.acc.org/qualityandscience/clinical/pdfs/Final_Dual_Antiplatelet_Statement_010507.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):7-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/22315257/pubmed\" target=\"_blank\" id=\"22315257\">22315257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hall R and Mazer CD, &quot;Antiplatelet Drugs: A Review of Their Pharmacology and Management in the Perioperative Period,&quot; <i>Anesth Analg</i>, 2011, 12(2):292-318.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/21212258/pubmed\" target=\"_blank\" id=\"21212258\">21212258</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo; <i>Circulation</i>, 2011, 124(23):2610-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/22064600/pubmed\" target=\"_blank\" id=\"22064600\">22064600</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kerneis M, Silvain J, Abtan J, et al, &ldquo;Switching Acute Coronary Syndrome Patients from Prasugrel to Clopidogrel,&rdquo; <i>JACC Cardiovasc Interv</i>, 2013, 6(2):158-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/23428007/pubmed\" target=\"_blank\" id=\"23428007\">23428007</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. <i>J Am Coll Cardiol</i>. 2016;pii: S0735-1097(16)01699-5. doi: 10.1016/j.jacc.2016.03.513.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/27036918/pubmed\" target=\"_blank\" id=\"27036918\">27036918</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo; <i>Circulation</i>, 2011, 124(23):e574-651.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/22064601/pubmed\" target=\"_blank\" id=\"22064601\">22064601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mauri L, Kereiakes DJ, Yeh RW, et al; the DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents [published online ahead of print November 16, 2014]. <i>N Engl J Med</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/25399658/pubmed\" target=\"_blank\" id=\"25399658\">25399658</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mega JL, Close SL, Wiviott SD, et al, &ldquo;Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes,&rdquo; <i>Circulation</i>, 2009, 119(19):2553-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/19414633/pubmed\" target=\"_blank\" id=\"19414633\">19414633</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O&rsquo;Donoghue ML, Braunwald E, Antman EM, et al, &ldquo;Pharmacodynamic Effect and Clinical Efficacy of Clopidogrel and Prasugrel With or Without a Proton Pump Inhibitor: an Analysis of Two Randomised Trials,&rdquo; <i>Lancet</i>, 2009, 374(9694):989-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/19726078/pubmed\" target=\"_blank\" id=\"19726078\">19726078</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23247304\"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2013;128(25):e481.] <i>Circulation</i>. 2013;127(4):e362-e425.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/23247304/pubmed\" target=\"_blank\" id=\"23247304\">23247304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Payne CD, Li YG, Brandt JT, et al, &ldquo;Switching Directly to Prasugrel from Clopidogrel Results in Greater Inhibition of Platelet Aggregation in Aggregation in Aspirin-treated Subjects,&rdquo; <i>Platelets</i>, 2008, 19(4):275-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/18569863/pubmed\" target=\"_blank\" id=\"18569863\">18569863</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Riesmeyer JS, Salazar DE, Weerakkody GJ, et al, &quot;Relationship Between Exposure to Prasugrel Active Metabolite and Clinical Outcomes in the TRITON-TIMI 38 Substudy,&quot; <i>J Clin Pharmacol</i>, 2012, 52(6):789-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/21628601/pubmed\" target=\"_blank\" id=\"21628601\">21628601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Riley AB, Tafreshi MJ, Haber SL. Prasugrel: a novel antiplatelet agent. <i>Am J Health Syst Pharm</i>. 2008;65(11):1019-1028.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/18499874/pubmed\" target=\"_blank\" id=\"18499874\">18499874</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roe MT, Armstrong PW, Fox KA, et al, &ldquo;Prasugrel versus Clopidogrel for Acute Coronary Syndromes Without Revascularization,&rdquo; <i>N Engl J Med</i>, 2012, 367(14):1297-309.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/22920930/pubmed\" target=\"_blank\" id=\"22920930\">22920930</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rollini F, Franchi F, Hu J, et al. Crushed prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary intervention: The CRUSH study. <i>J Am Coll Cardiol</i>. 2016;67(17):1994-2004. doi: 10.1016/j.jacc.2016.02.045.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/27012781/pubmed\" target=\"_blank\" id=\"27012781\">27012781</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Serebruany VL, &ldquo;Mortality in the TRITON Trial: Update from the FDA Prasugrel Action Package,&rdquo; <i>Am J Cardio</i>l, 2010, 105(9):1356-7</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo; <i>Circulation</i>, 2011, 124(22):2458-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/22052934/pubmed\" target=\"_blank\" id=\"22052934\">22052934</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Strate LL, Gralnek IM. ACG clinical guideline: management of patients with acute lower gastrointestinal bleeding. <i>Am J Gastroenterol</i>. 2016;111(4):459-474. doi: 10.1038/ajg.2016.41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/26925883/pubmed\" target=\"_blank\" id=\"26925883\">26925883</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tello-Montoliu A, Seecheran NA, and Angiolillo DJ, &quot;Successful Pregnancy and Delivery on Prasugrel Treatment: Considerations for the Use of Dual Antiplatelet Therapy During Pregnancy in Clinical Practice,&quot; <i>J Thromb Thrombolysis</i>, 2012, Nov 10 [Epub ahead of print].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wiviott SD, Braunwald E, McCabe CH, et al, &ldquo;Intensive Oral Antiplatelet Therapy for Reduction of Ischaemic Events Including Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Percutaneous Coronary Intervention and Stenting in the TRITON-TIMI 38 Trial: A Subanalysis of a Randomised Trial,&rdquo; <i>Lancet</i>, 2008, 371(9621):1353-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/18377975/pubmed\" target=\"_blank\" id=\"18377975\">18377975</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wiviott SD, Braunwald E, McCabe CH, et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. <i>N Engl J Med</i>. 2007;357(20):2001-2015.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/17982182/pubmed\" target=\"_blank\" id=\"17982182\">17982182</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wiviott SD, Trenk D, Frelinger AL, et al; PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. <i>Circulation</i>. 2007;116(25):2923-2932.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/18056526/pubmed\" target=\"_blank\" id=\"18056526\">18056526</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yeh RW, Secemsky EA, Kereiakes DJ, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. <i>JAMA</i>. 2016;315(16):1735-1749. doi: 10.1001/jama.2016.3775.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/27022822/pubmed\" target=\"_blank\" id=\"27022822\">27022822</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9533 Version 153.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F11238845\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F7901908\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F14464693\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F7910294\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F7912224\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F7910728\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F7910729\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F7910730\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F7910736\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F7910292\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7984963\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F7910732\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F7910296\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F10227670\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F7910605\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F7910301\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F7910302\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299935\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8018470\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F7910298\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20311220\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F7910734\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F7910614\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F7910616\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322568\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10962010\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9533|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=prasugrel-patient-drug-information\" class=\"drug drug_patient\">Prasugrel: Patient drug information</a></li></ul></div></div>","javascript":null}